NCT02617277 2026-03-04Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid TumoursAstraZenecaPhase 1 Completed56 enrolled
NCT05508334 2025-12-22A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid TumoursRemeGen Co., Ltd.Phase 1/2 Completed41 enrolled